Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trasylol Linked To Increased Long-Term Mortality In CABG Patients – JAMA

Executive Summary

Bayer's Trasylol (aprotinin) is associated with an increased risk of death in the five years following coronary artery bypass graft surgery (CABG), according to a study published in the Feb. 7 Journal of the American Medical Association

You may also be interested in...



Trasylol Label Should Get Warning, But Not Study Details Advisory Cmte. Says

Following a Sept. 12 advisory committee meeting evaluating safety signals for Bayer's Trasylol (aprotinin), FDA faces the question of how to re-label a drug with uncertain but serious risks

Safety Trials In Trasylol ’s Future, But Design Could Prove Challenging

FDA and Bayer will begin discussions of post-marketing studies for the firm's Trasylol (aprotinin) due to suggestive but inconclusive observational data linking the drug to renal events and death

Trasylol Label Should Get Warning, But Not Study Details Advisory Cmte. Says

Following a Sept. 12 advisory committee meeting evaluating safety signals for Bayer's Trasylol (aprotinin), FDA faces the question of how to re-label a drug with uncertain but serious risks

UsernamePublicRestriction

Register

LL1129949

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel